CABOZANTINIB
Information current as at: 1 June 2026
The pharmaceutical company has not advised whether they intend to proceed or not within 60 days of receiving the ratified PBAC minutes. The process for listing is considered inactive.
Submission Details
- Brand name:
-
- Cabometyx®
- Form and strength:
- Please search for and view the medicine's Public Summary Document (PSD) for more information
- Condition/indication:
(therapeutic use) -
- Advanced clear cell variant renal cell carcinoma in combination with nivolumab
- Listing requested:
- Please see PSD for more information
- Funding program:
- Please see PSD for more information
- Request authority level:
- Please see PSD for more information
- PBAC submission type:
- Change to existing listing (Category 2)
- Comment:
- --
- Submission sponsor:
- Ipsen Pty Ltd
- Other PBAC consideration:
- --
Progress Details
-
Submission received for: - March 2024 PBAC meeting
-
Opportunity for consumer comment: - Open 22/11/2023 and close 31/01/2024 (see PBS Website)
-
PBAC meeting: - Held on 13/03/2024
-
PBAC outcome published: - Recommended (see PBAC Outcomes)
-
Notice of intent submitted:
- Awaiting lodgement from pharmaceutical company
-
5Lodgement of required documentation:
- Has not yet commenced
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
PBAC Outcome
Case ID: a820
Page last updated: 31 March 2026